Immunodominance of H60 is caused by an abnormally high precursor T cell pool directed against its unique minor histocompatibility antigen peptide

Immunity

Volumn 17, Issue 5, 2002, Pages 593-603

  Choi, Eun Young ^a   Christianson, Gregory J ^a   Yoshimura, Yoshitaka ^b   Sproule, Thomas J ^a   Jung, Nadja ^a   Joyce, Sebastian ^b   Roopenian, Derry C ^a  

^a JACKSON LABORATORY   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; CD8 ANTIGEN; GLYCOPROTEIN; H60 GLYCOPROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN; MINOR HISTOCOMPATIBILITY ANTIGEN; UNCLASSIFIED DRUG; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; DOMINANT GENE; EVOKED RESPONSE; FEMALE; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; RAT; STEM CELL; T LYMPHOCYTE; TISSUE TRANSPLANTATION;

EID: 0036850785     PISSN: 10747613     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-7613(02)00428-4     Document Type: Article

References (49)

1. Auchincloss H. Jr., Sultan H. Antigen processing and presentation in transplantation. Curr. Opin. Immunol. 8:1996;681-687.
2. Belz G.T., Xie W., Altman J.D., Doherty P.C. A previously unrecognized H-2Db-restricted peptide prominent in the primary influenza A virus-specific CD8+ T-cell response is much less apparent following secondary challenge. J. Virol. 74:2000;3486-3493.
3. Bevan M.J. The major histocompatibility complex determines susceptibility to cytotoxic T cells directed against minor histocompatibility antigens. J. Exp. Med. 142:1975;1349-1364.
4. Carayannopoulos L.N., Naidenko O.V., Kinder J., Ho E.L., Fremont D.H., Yokoyama W.M. Ligands for murine NKG2D display heterogeneous binding behavior. Eur. J. Immunol. 32:2002;597-605.
5. Cerwenka A., Bakker A.B., McClanahan T., Wagner J., Wu J., Phillips J.H., Lanier L.L. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity. 12:2000;721-727.
6. Cerwenka A., O'Callaghan C.A., Hamerman J.A., Yadav R., Ajayi W., Roopenian D.C., Joyce S., Lanier L.L. Cutting edge. the minor histocompatibility antigen H60 peptide interacts with both H-2Kb and NKG2D J. Immunol. 168:2002;3131-3134.
7. Chen W., Anton L.C., Bennink J.R., Yewdell J.W. Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses. Immunity. 12:2000;83-93.
8. Chen W., Calvo P.A., Malide D., Gibbs J., Schubert U., Bacik I., Basta S., O'Neill R., Schickli J., Palese P.et al. A novel influenza A virus mitochondrial protein that induces cell death. Nat. Med. 7:2001;1306-1312.
9. Choi E.Y., Christianson G.J., Yoshimura Y., Jung N., Sproule T.J., Malarkannan S., Joyce S., Roopenian D.C. Real-time T cell profiling identifies H60 as a major minor histocompatibility antigen in murine graft vs host disease. Blood. in press:2002.
10. Choi E.Y., Yoshimura Y., Christianson G.J., Sproule T.J., Malarkannan S., Shastri N., Joyce S., Roopenian D.C. Quantitative analysis of the immune response to mouse non-MHC transplantation antigens in vivo. the H60 histocompatibility antigen dominates over all others J. Immunol. 166:2001;4370-4379.
11. Correia-Neves M., Mathis D., Benoist C. A molecular chart of thymocyte positive selection. Eur. J. Immunol. 31:2001;2583-2592.
12. Diefenbach A., Jamieson A.M., Liu S.D., Shastri N., Raulet D.H. Ligands for the murine NKG2D receptor. expression by tumor cells and activation of NK cells and macrophages Nat. Immunol. 1:2000;119-126.
13. Diefenbach A., Jensen E.R., Jamieson A.M., Raulet D.H. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature. 413:2001;165-171.
14. Eden P.A., Christianson G.J., Fontaine P., Wettstein P.J., Perreault C., Roopenian D.C. Biochemical and immunogenetic analysis of an immunodominant peptide (B6dom1) encoded by the classical H7 minor histocompatibility locus. J. Immunol. 162:1999;4502-4510.
15. Girardi M., Oppenheim D.E., Steele C.R., Lewis J.M., Glusac E., Filler R., Hobby P., Sutton B., Tigelaar R.E., Hayday A.C. Regulation of cutaneous malignancy by γδ T cells. Science. 294:2001;605-609.
16. Gordon R.D., Simpson E., Samelson L.E. In vitro cell-mediated immune responses to the male specific (H-Y) antigen in mice. J. Exp. Med. 142:1975;1108-1120.
17. Greenfield A., Scott D., Pennisi D., Ehrmann I., Ellis P., Cooper L., Simpson E., Koopman P. An H-YDb epitope is encoded by a novel mouse Y chromosome gene. Nat. Genet. 14:1996;474-478.
18. Grufman P., Wolpert E.Z., Sandberg J.K., Karre K. T cell competition for the antigen-presenting cell as a model for immunodominance in the cytotoxic T lymphocyte response against minor histocompatibility antigens. Eur. J. Immunol. 29:1999;2197-2204.
19. Jamieson A.M., Diefenbach A., McMahon C.W., Xiong N., Carlyle J.R., Raulet D.H. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity. 17:2002;19-29.
20. Kedl R.M., Rees W.A., Hildeman D.A., Schaefer B., Mitchell T., Kappler J., Marrack P. T cells compete for access to antigen-bearing antigen-presenting cells. J. Exp. Med. 192:2000;1105-1113.
21. Kedl R.M., Schaefer B.C., Kappler J.W., Marrack P. T cells down-modulate peptide-MHC complexes on APCs in vivo. Nat. Immunol. 3:2002;27-32.
22. Luckey C.J., Marto J.A., Partridge M., Hall E., White F.M., Lippolis J.D., Shabanowitz J., Hunt D.F., Engelhard V.H. Differences in the expression of human class I MHC alleles and their associated peptides in the presence of proteasome inhibitors. J. Immunol. 167:2001;1212-1221.
23. MacDonald H.R., Cerottini J.C., Ryser J.E., Maryanski J.L., Taswell C., Widmer M.B., Brunner K.T. Quantitation and cloning of cytolytic T lymphocytes and their precursors. Immunol. Rev. 51:1980;93-123.
24. Malarkannan S., Shih P.P., Eden P.A., Horng T., Zuberi A.R., Christianson G., Roopenian D., Shastri N. The molecular and functional characterization of a dominant minor H antigen, H60. J. Immunol. 161:1998;3501-3509.
25. Malarkannan S., Horng T., Eden P., Gonzalez F., Shih P., Brouwenstijn N., Klinge H., Christianson G., Roopenian D., Shastri N. Differences that matter. major cytotoxic T cell-stimulating minor histocompatibility antigens Immunity. 13:2000;333-344.
26. Manjunath N., Shankar P., Wan J., Weninger W., Crowley M.A., Hieshima K., Springer T.A., Fan X., Shen H., Lieberman J., von Andrian U.H. Effector differentiation is not prerequisite for generation of memory cytotoxic T lymphocytes. J. Clin. Invest. 108:2001;871-878.
27. Martin S., Dyer P.A. The case for matching MHC genes in human organ transplantation. Nat. Genet. 5:1993;210-213.
28. Meadows L., Wang W., den Haan J.M., Blokland E., Reinhardus C., Drijfhout J.W., Shabanowitz J., Pierce R., Agulnik A.I., Bishop C.E.et al. The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity. 6:1997;273-281.
29. Mendoza L.M., Paz P., Zuberi A., Christianson G., Roopenian D., Shastri N. Minors held by majors. the H13 minor histocompatibility locus defined as a peptide/MHC class I complex Immunity. 7:1997;461-472.
30. Millrain M., Chandler P., Dazzi F., Scott D., Simpson E., Dyson P.J. Examination of HY response. T cell expansion, immunodominance, and cross-priming revealed by HY tetramer analysis J. Immunol. 167:2001;3756-3764.
31. Mutis T., Gillespie G., Schrama E., Falkenburg J.H., Moss P., Goulmy E. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Nat. Med. 5:1999;839-842.
32. Nevala W.K., Wettstein P.J. H4 and CTT-2 minor histocompatibility antigens. concordant genetic linkage and migration in two-dimensional peptide separation Immunogenetics. 44:1996;400-404.
33. Ono T., DiLorenzo T.P., Wang F., Kalergis A.M., Nathenson S.G. Alterations in TCR-MHC contracts subsequent to cross-recognition of class I MHC and singly substituted peptide variants. J. Immunol. 161:1998;5454-5463.
34. Perreault C., Roy D.C., Fortin C. Immunodominant minor histocompatibility antigens. the major ones Immunol. Today. 19:1998;69-74.
35. Pimsler M., Forman J. Estimates of the precursor frequency of cytotoxic T lymhocytes against antigens controlled by defined regions of the H-2 gene complex. comparison of the effect of H-2 differences due to intra-H-2 recombination vs mutation J. Immunol. 121:1978;1302-1305.
36. Pittet M.J., Valmori D., Dunbar P.R., Speiser D.E., Lienard D., Lejeune F., Fleischhauer K., Cerundolo V., Cerottini J.C., Romero P. High frequencies of naive Melan-A/MART-1-specific CD8+ T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J. Exp. Med. 190:1999;705-715.
37. Roopenian D.C., Widmer M.B., Orosz C.G., Bach F.H. Response against single minor histocompatibility antigens. I. Functional and immunogenetic analysis of cloned cytolytic T cells. J. Immunol. 131:1983;2135-2140.
38. Scott D.M., Ehrmann I.E., Ellis P.S., Bishop C.E., Agulnik A.I., Simpson E., Mitchell M.J. Identification of a mouse male-specific transplantation antigen, H-Y. Nature. 376:1995;695-698.
39. Simpson E., Roopenian D. Minor histocompatibility antigens. Curr. Opin. Immunol. 9:1997;655-661.
40. Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies. III. Validity tests for the single-hit Poisson model. J. Immunol. Methods. 72:1984;29-40.
41. Teh H.S., Bennink J., Von Boehmer H. Selection of the T cell repertoire during ontogeny. limiting dilution analysis Eur. J. Immunol. 12:1982;887-892.
42. Theobald M., Bunjes D. Pretransplant detection of human minor histocompatibility antigen- specific naive and memory interleukin-2-secreting T cells within class I major histocompatibility complex (MHC)-restricted CD8+ and class II MHC-restricted CD4+ T-cell subsets. Blood. 82:1993;298-306.
43. b molecule. Nature. 348:1990;213-216.
44. van der Bruggen P. Antigens recognized on human tumors by cytolytic T lymphocytes. Towards vaccination? Roopenian D.C., Simpson E. Minor Histocompatibility Antigens. From the Laboratory to the Clinic:2000;Landes Bioscience, Georgetown. 171-182.pp.
45. Vidal K., Hsu B.L., Williams C.B., Allen P.M. Endogenous altered peptide ligands can affect peripheral T cell responses. J. Exp. Med. 183:1996;1311-1321.
46. Wang W., Meadows L.R., den Haan J.M., Sherman N.E., Chen Y., Blokland E., Shabanowitz J., Agulnik A.I., Hendrickson R.C., Bishop C.E.et al. Human H-Y. a male-specific histocompatibility antigen derived from the SMCY protein Science. 269:1995;1588-1590.
47. Weninger W., Crowley M.A., Manjunath N., von Andrian U.H. Migratory properties of naive, effector, and memory CD8+ T cells. J. Exp. Med. 194:2001;953-966.
48. Yewdell J.W., Bennink J.R. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol. 17:1999;51-88.
49. Zippelius A., Pittet M.J., Batard P., Rufer N., de Smedt M., Guillaume P., Ellefsen K., Valmori D., Lienard D., Plum J.et al. Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J. Exp. Med. 195:2002;485-494.